Logo image of ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ESLA - US2975841048 - Common Stock

1.44 USD
+0.07 (+5.11%)
Last: 1/7/2026, 8:00:02 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ESLA. ESLA was compared to 530 industry peers in the Biotechnology industry. ESLA has a bad profitability rating. Also its financial health evaluation is rather negative. ESLA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ESLA has reported negative net income.
ESLA had a negative operating cash flow in the past year.
ESLA had negative earnings in each of the past 5 years.
In the past 5 years ESLA always reported negative operating cash flow.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of ESLA (-383.16%) is worse than 93.02% of its industry peers.
Industry RankSector Rank
ROA -383.16%
ROE N/A
ROIC N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ESLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, ESLA has more shares outstanding
There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ESLA has an Altman-Z score of -28.63. This is a bad value and indicates that ESLA is not financially healthy and even has some risk of bankruptcy.
ESLA has a worse Altman-Z score (-28.63) than 86.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.63
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 0.15 indicates that ESLA may have some problems paying its short term obligations.
The Current ratio of ESLA (0.15) is worse than 93.77% of its industry peers.
A Quick Ratio of 0.15 indicates that ESLA may have some problems paying its short term obligations.
The Quick ratio of ESLA (0.15) is worse than 93.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

ESLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -55.40%.
EPS 1Y (TTM)-55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ESLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.03% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as ESLA's earnings are expected to decrease with -67.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%

More info and screens

0

5. Dividend

5.1 Amount

ESLA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (1/7/2026, 8:00:02 PM)

1.44

+0.07 (+5.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)N/A N/A
Inst Owners1.97%
Inst Owner Change0%
Ins Owners2.12%
Ins Owner Change0%
Market Cap54.39M
Revenue(TTM)N/A
Net Income(TTM)-13.50M
Analysts82.86
Price Target16.32 (1033.33%)
Short Float %6.07%
Short Ratio2.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -383.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -28.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.69%
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-503.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-503.13%
OCF growth 3YN/A
OCF growth 5YN/A

ESTRELLA IMMUNOPHARMA INC / ESLA FAQ

What is the ChartMill fundamental rating of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ESLA.


Can you provide the valuation status for ESTRELLA IMMUNOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to ESTRELLA IMMUNOPHARMA INC (ESLA). This can be considered as Overvalued.


How profitable is ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ESTRELLA IMMUNOPHARMA INC (ESLA) has a profitability rating of 0 / 10.


What is the financial health of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

The financial health rating of ESTRELLA IMMUNOPHARMA INC (ESLA) is 0 / 10.


What is the expected EPS growth for ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

The Earnings per Share (EPS) of ESTRELLA IMMUNOPHARMA INC (ESLA) is expected to decline by -132.85% in the next year.